Eidos Therapeutics, Inc. (EIDX): Price and Financial Metrics

Eidos Therapeutics, Inc. (EIDX)

Today's Latest Price: $49.27 USD

1.23 (2.56%)

Updated Jul 2 4:00pm

Add EIDX to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 214 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

EIDX Stock Summary

  • Eidos Therapeutics Inc's stock had its IPO on June 20, 2018, making it an older stock than merely 4.85% of US equities in our set.
  • EIDX's price/sales ratio is 68.83; that's higher than the P/S ratio of 96.92% of US stocks.
  • With a year-over-year growth in debt of 1,799.2%, Eidos Therapeutics Inc's debt growth rate surpasses 98.81% of about US stocks.
  • Stocks that are quantitatively similar to EIDX, based on their financial statements, market capitalization, and price volatility, are RCUS, NTLA, DTIL, KALV, and SGMO.
  • Visit EIDX's SEC page to see the company's official filings. To visit the company's web site, go to www.eidostx.com.
EIDX Daily Price Range
EIDX 52-Week Price Range

EIDX Stock Price Chart Technical Analysis Charts

EIDX Price/Volume Stats

Current price $49.27 52-week high $66.56
Prev. close $48.04 52-week low $28.00
Day low $48.13 Volume 49,016
Day high $49.77 Avg. volume 114,517
50-day MA $46.81 Dividend yield N/A
200-day MA $48.58 Market Cap 1.90B

Eidos Therapeutics, Inc. (EIDX) Company Bio

Eidos Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) amyloidosis (ATTR). It is developing AG10, an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR. The company was incorporated in 2013 and is headquartered in San Francisco, California. Eidos Therapeutics, Inc. is a subsidiary of BridgeBio Pharma LLC.

EIDX Latest News Stream

Event/TimeNews Detail
Loading, please wait...

EIDX Latest Social Stream

Loading social stream, please wait...

View Full EIDX Social Stream

Latest EIDX News From Around the Web

Below are the latest news stories about Eidos Therapeutics Inc that investors may wish to consider to help them evaluate EIDX as an investment opportunity.

Eidos Therapeutics (EIDX) Looks Good: Stock Adds 6.4% in Session

Eidos Therapeutics (EIDX) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

Yahoo | July 1, 2020

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Eidos Therapeutics, Inc. - EIDX

Pomerantz LLP is investigating claims on behalf of investors of Eidos Therapeutics, Inc. (“Eidos” or the “Company”) (NASDAQ: EIDX). The investigation concerns whether Eidos and certain of its officers and/or directors have breached fiduciary duties owed to the company and its investors. If you are a shareholder of Eidos and are interested in obtaining additional information regarding this investigation,  you are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext.

Yahoo | June 11, 2020

Eidos Therapeutics Reports First Quarter 2020 Financial Results and Business Update

SAN FRANCISCO, May 08, 2020 -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX),  today reported its financial results for the first quarter ended March 31, 2020 and provided an.

Yahoo | May 8, 2020

Hedge Funds Have Never Been This Bullish On Eidos Therapeutics, Inc. (EIDX)

Coronavirus is probably the 1 concern in investors' minds right now. It should be. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW. We predicted that a US recession is imminent and US stocks will go down by at least 20% in the next 3-6 […]

Yahoo | April 7, 2020

5 Guru Stocks That Beat the Market

Enphase Energy makes the list Continue reading...

Yahoo | March 31, 2020

Read More 'EIDX' Stories Here

EIDX Price Returns

1-mo -4.33%
3-mo 12.26%
6-mo -16.05%
1-year 34.54%
3-year N/A
5-year N/A
YTD -14.15%
2019 317.08%
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.8172 seconds.